分清化浊胶囊对阿霉素肾病大鼠的影响

目的 观察分清化浊胶囊对阿霉素肾病大鼠的影响及其可能的作用机制。方法 将雄性SD大鼠随机分为6组（对照组，模型组，阳性对照组，分清化浊胶囊低、中、高剂量组），除对照组外，其余各组大鼠采用尾iv阿霉素法制成阿霉素肾病大鼠模型，第一次尾iv阿霉素（4 mg/kg）1周后，第二次iv阿霉素（3.5 mg/kg）。造模成功后，对照组和模型组ig生理盐水，阳性对照组ig黄葵胶囊混悬液；其余治疗组ig分清化浊胶囊混悬液。每日一次，疗程4周。观察大鼠一般情况，在给药前、给药7、14、21、28 d测定24 h尿蛋白定量，末次给药后，测定大鼠血清总蛋白（TP）、白蛋白（ALB）、总胆固醇（TC）、三酰甘油（TG）、血尿素氮（BUN）、肌酐（Cr），并观察大鼠肾脏病理变化。结果 治疗前，与对照组比较，各治疗组尿蛋白定量有显著差异（P＜0.01），说明造模成功；阳性组、分清化浊胶囊各剂量组均能显著降低尿蛋白（P＜0.01）。与模型组比较，分清化浊胶囊高、中剂量能升高TP、ALB水平（P＜0.01）。分清化浊胶囊高、中剂量对TG及TC有降低作用（P＜0.01）。各治疗组对肾功能指标BUN、Cr无明显影响。各治疗组肾脏病变程度较模型组有明显减轻。结论 分清化浊胶囊可以显著降低阿霉素肾病大鼠尿蛋白、TC、TG；明显升高阿霉素肾病大鼠TP、ALB水平，减轻肾脏病理损害。

Effects of Fenqing Huazhuo Capsule on Adriamycin-induced nephrosis rats

Objective To study the effect and the possible mechanism of Fenqing Huazhuo Capsule (FHC) on Adrianycin-induced nephrosis rats. Methods Sixty SD rats were randomly divided into six groups (control, model, positive control, low-, mid-, and high-dose FHC groups), all the rats except those in the control group were tail-intravenously injected with Adriamycin to establish the animal model, in 4 mg/kg for the first time and one week later in 3.5 mg/kg for the second time. After the model establishment, rats in the control and model groups were ig administered with physiological saline, rats in the positive control group were ig administered with Huangkui Capsule suspension, and rats in the other treatment groups were ig administered with FHC suspension, once daily for four weeks. The situation of the rats was observed, 24 h urinary protein was determinated before administration; On the day 7, 14, 21, and 28 after the last administration, the total protein (TP), albumin (Alb), total cholesterol (TC), triacylglycerol (TG), blood urea nitrogen (BUN), and creatinine (CR) in serum were determined after the last adminnistration,and the pathological changes in kidney were observed. Results Before the treatment, the urine protein of each treatment group was significantly different (P < 0.01) compared with the control group; the urinary protein could be significantly reduced (P < 0.01) in the positive control and FHC treatment groups. Compared with the model group, the contents of TP and ALB in the high- and mid-dose FHC groups could be increased (P < 0.01). The levels of TG and TC in the high- and mid-dose FHC groups could be reduced. There was little effect on the index of renal function in the treatment groups, which indicated that the pathological changes of kidney could be significantly reduced. Conclusion Each dosage of FHC could decrease the contents of the urinary protein, TC, and TG, increase the contents of TP and ALB in serum, and lighten the pathological lesion of kidney.